Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Inflammatory and long-term risk markers.

Stanley S Levinson1

  • 1Department of Pathology and Laboratory Medicine and Laboratory Service, Department of Veterans Affairs Medical Center, 800 Zorn Avenue, Louisville, KY 40206, USA. levinson@louisville.edu

Clinics in Laboratory Medicine
|August 30, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Putting clinical studies into better perspective by defining accuracy when effect size is small.

Clinica chimica acta; international journal of clinical chemistry·2025
Same author

Non-HDL Cholesterol May Be Preferred over Apolipoprotein B-100 for Risk Assessment when Evaluated by Receiver Operator Characteristic Curve Analysis.

The journal of applied laboratory medicine·2024
Same author

Accuracy of the Number Needed to Treat Compared With Diagnostic Testing: Brief Critical Review.

Archives of pathology & laboratory medicine·2022
Same author

Is Measurement of Systemic IgG Antibodies the Wrong Way to Assess COVID-19 Vaccine Effectiveness for Breakthrough Infections?

The journal of applied laboratory medicine·2022
Same author

The Predicament of Large Numbers of Observations and How We Got There: Critical Review.

The journal of applied laboratory medicine·2020
Same author

SARS-CoV-2 Serology-Need for Quantitative Testing and Interpretive Reporting.

The journal of applied laboratory medicine·2020
Same journal

Advances in Hemostasis Laboratory Testing.

Clinics in laboratory medicine·2026
Same journal

Extracellular Vesicles in Hemostasis.

Clinics in laboratory medicine·2026
Same journal

Thrombin Generation Assay: Ready for Prime Time.

Clinics in laboratory medicine·2026
Same journal

Viscoelastic Testing for the Laboratorian: Recent Advances and Practical Advice.

Clinics in laboratory medicine·2026
Same journal

Practical Recommendations for Harmonization of Hemostasis Testing Across Hospital Sites.

Clinics in laboratory medicine·2026
Same journal

The Role of Hypoxia in Vascular Endothelial Dysfunction and Venous Thromboembolism.

Clinics in laboratory medicine·2026
See all related articles

Inflammatory markers like C-reactive protein show potential for predicting atherosclerosis risk. However, no current markers meet criteria for routine clinical screening and risk stratification.

Area of Science:

  • Cardiovascular Medicine
  • Inflammation Research
  • Biomarker Discovery

Background:

  • Atherosclerosis is a complex disease with a significant inflammatory component.
  • Inflammation plays a crucial role in the development and progression of atherosclerotic plaques.
  • Identifying reliable inflammatory markers is key for assessing cardiovascular disease risk.

Purpose of the Study:

  • To review the evidence for inflammatory markers in atherosclerosis risk prediction.
  • To evaluate the clinical utility of specific inflammatory markers.
  • To discuss criteria for clinically useful diagnostic and prognostic tests.

Main Methods:

  • Systematic review of studies evaluating fibrinogen, hs-CRP, IL-6, MPO, and sCD40L.
  • Analysis of relative risk and clinical utility criteria for risk assessment tools.

Related Experiment Videos

  • Discussion of the challenges in establishing marker usefulness for clinical practice.

    • Main Results:

    • Current evidence does not establish clinically useful inflammatory markers for routine atherosclerosis screening or risk stratification.
    • Prospective studies are required to validate the predictive value of existing markers.
    • Significant challenges exist in demonstrating that current inflammatory markers meet the necessary criteria for clinical application.

    Conclusions:

    • Clinically validated inflammatory markers for atherosclerosis risk prediction are not yet established.
    • Further research, including robust prospective studies, is needed to confirm the utility of current markers.
    • Understanding the fundamental mechanisms of inflammation in atherosclerosis may be essential for discovering truly predictive biomarkers.